Status:

COMPLETED

The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Conditions:

HIV Infection

Yellow Fever

Eligibility:

All Genders

18-55 years

Phase:

PHASE3

Brief Summary

Main objective : To develop the tools for evaluation of humoral and cell-mediated immunity after Yellow Fever Vaccine (YFV) and compare virological and immune responses in HIV-positive and HIV-negati...

Detailed Description

Method : Clinical Trial Phase III, Multicentre protocol at Saint-Louis hospital, Bichat hospital and Cochin-Pasteur hospital, with CERVI, INSERM U 941 and SC10 collaboration. Trial treatment : Yello...

Eligibility Criteria

Inclusion

  • Group 1: Voluntary HIV positive subjects
  • Adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment)
  • \> 350 CD4/mm3 (with half of them a nadir \< 200 CD4/mm3) and a viral load \< 50 copies/mL for at least 6 months.
  • Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.

Exclusion

  • Previous vaccination against yellow fever or yellow fever Fluorescence anti-IgG positive.
  • Administration of immunoglobulins \< 3 months or any vaccine \<1 month.
  • Pregnancy ongoing or planned during the study.
  • Coinfection with HCV virus untreated.
  • HBs Ag positive.
  • Hypersensitivity reaction to eggs / chicken protein; hereditary fructose intolerance.
  • Immunosuppression, whether congenital, idiopathic or as a result of corticosteroids systemically (at doses ≥ 20mg/d of prednisone), or due to radiation or antineoplastic older than 6 months.
  • History of thymic dysfunction (including thymoma and thymectomy).
  • For HIV + subjects: ART Celsentri or by other anti-CCR5.
  • Group 2: HIV negative subjects
  • Inclusion Criteria:
  • HIV and HCV negatives

Key Trial Info

Start Date :

July 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2017

Estimated Enrollment :

71 Patients enrolled

Trial Details

Trial ID

NCT01426243

Start Date

July 1 2011

End Date

December 1 2017

Last Update

January 18 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Voir Liste Des Centres

Paris, France

The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. | DecenTrialz